[go: up one dir, main page]

MX2018008185A - Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe. - Google Patents

Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.

Info

Publication number
MX2018008185A
MX2018008185A MX2018008185A MX2018008185A MX2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A MX 2018008185 A MX2018008185 A MX 2018008185A
Authority
MX
Mexico
Prior art keywords
glucosidase
pompe disease
treatment
acid alpha
recombinant human
Prior art date
Application number
MX2018008185A
Other languages
English (en)
Other versions
MX394968B (es
Inventor
Khanna Richie
Gotschall Russell
V Do Hung
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2018008185A publication Critical patent/MX2018008185A/es
Publication of MX394968B publication Critical patent/MX394968B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para tratar la enfermedad de Pompe que incluye la administración de a-glucosidasa ácida humana recombinante que tiene una glucosilación óptima con residuos de manosa-6-fosfato junto con una cantidad de miglustat eficaz para maximizar la captación en tejidos de la a-glucosidasa ácida humana recombinante a la vez que se minimiza la inhibición de la actividad enzimática de la a-glucosidasa ácida humana recombinante.
MX2018008185A 2015-12-30 2016-12-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe. MX394968B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08
US15/394,135 US20170189497A1 (en) 2015-12-30 2016-12-29 Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
PCT/US2016/069243 WO2017117407A1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease

Publications (2)

Publication Number Publication Date
MX2018008185A true MX2018008185A (es) 2018-08-28
MX394968B MX394968B (es) 2025-03-24

Family

ID=57822129

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008185A MX394968B (es) 2015-12-30 2016-12-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
MX2022010311A MX2022010311A (es) 2015-12-30 2018-06-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010311A MX2022010311A (es) 2015-12-30 2018-06-29 Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.

Country Status (15)

Country Link
US (5) US20170189497A1 (es)
JP (4) JP2019501178A (es)
KR (3) KR102510941B1 (es)
AU (2) AU2016381832B2 (es)
BR (1) BR112018013151A2 (es)
CA (1) CA3010205A1 (es)
CL (1) CL2018001773A1 (es)
CO (1) CO2018007680A2 (es)
EA (1) EA201891507A1 (es)
IL (3) IL299470A (es)
MX (2) MX394968B (es)
MY (1) MY198085A (es)
PH (1) PH12018501313B1 (es)
SG (1) SG11201804965SA (es)
WO (1) WO2017117407A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3900702A1 (en) 2015-03-19 2021-10-27 Translate Bio, Inc. Mrna therapy for pompe disease
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
CA3019128A1 (en) * 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US11944628B2 (en) 2017-05-12 2024-04-02 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
DK3624831T5 (da) * 2017-05-15 2024-09-02 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
MA50546A (fr) 2017-06-07 2020-09-16 Regeneron Pharma Compositions et méthodes pour l'internalisation d'enzymes
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
AU2019269685B2 (en) 2018-05-17 2025-12-04 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
AU2020343680A1 (en) 2019-09-06 2022-03-24 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
AU2020408066A1 (en) 2019-12-20 2022-06-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
US20240197839A1 (en) * 2021-02-11 2024-06-20 Amicus Therapeutics, Inc. Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
EP4518885A1 (en) * 2022-05-05 2025-03-12 Amicus Therapeutics, Inc. Methods for treating pompe disease
WO2025064350A1 (en) * 2023-09-18 2025-03-27 AskBio Inc. Therapeutic adeno-associated virus using nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with heterologous signal peptide

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020073438A1 (en) 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US20020013953A1 (en) 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
AU753336B2 (en) 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PT2020438T (pt) 1998-12-07 2018-07-13 Genzyme Corp Tratamento da doença de pompe
EP1165080A2 (en) 1999-02-12 2002-01-02 G.D. SEARLE & CO. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU6050600A (en) 1999-07-26 2001-02-13 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2001271941B2 (en) 2000-07-18 2007-03-01 Duke University Treatment of glycogen storage disease type II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
AU2002256423B2 (en) 2001-04-30 2008-07-24 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
JP2005523882A (ja) 2001-10-16 2005-08-11 アールエックスキネティックス，インコーポレイテッド 高濃度タンパク質製剤および製造の方法
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
PT2444102E (pt) 2003-01-31 2015-09-17 Sinai School Medicine Terapia combinada para o tratamento de distúrbios de deficiência proteica
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CA2556245A1 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
US20050244400A1 (en) 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
EP2099523A2 (en) 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
US8759501B2 (en) 2007-01-18 2014-06-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2252288A1 (en) 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
HUE026543T2 (hu) 2008-02-12 2016-06-28 Amicus Therapeutics Inc Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére
JP2011517556A (ja) 2008-03-12 2011-06-16 アミカス セラピューティックス インコーポレイテッド ポンペ病のための治療選択肢を診断し評価するための検定
CA2718182A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
BRPI0912225A2 (pt) 2008-05-07 2018-03-20 Zystor Therapeutics, Inc. peptídeos de direcionamento lisossomais e usos dos mesmos
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
PT2465542E (pt) 2008-12-16 2015-04-16 Genzyme Corp Conjugados oligossacárido-proteína
WO2010096369A1 (en) 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
CA2758271C (en) 2009-04-09 2018-06-05 Robert Boyd Methods for preventing and/or treating lysosomal storage disorders
EP2435459B1 (en) 2009-05-26 2016-05-04 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of acid beta-glucosidase
EP3075386B1 (en) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
SG189108A1 (en) 2010-09-29 2013-05-31 Oxyrane Uk Ltd Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
CA2833371A1 (en) * 2011-04-22 2012-10-26 Genzyme Corporation Modified acid alpha glucosidase with accelerated processing
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
US9512463B2 (en) 2011-11-08 2016-12-06 University Of Washington Methods and compositions for assaying the activity of one or more lysosomal enzymes
JP6320931B2 (ja) 2011-12-22 2018-05-09 セントジーン アイピー ゲーエムベーハー リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ
KR20140135222A (ko) 2012-03-07 2014-11-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
HUE053565T2 (hu) 2012-05-03 2021-07-28 Amicus Therapeutics Inc Adagolási rendek Pompe betegség kezelésére
AU2013273473B2 (en) 2012-06-06 2016-05-26 Consiglio Nazionale Delle Ricerche Allosteric chaperones and uses thereof
CA2917995C (en) 2012-07-17 2021-01-26 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
WO2014110270A1 (en) 2013-01-09 2014-07-17 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
RU2685269C2 (ru) 2013-12-23 2019-04-17 БКН Пептидес, С.А. Аналоги бикалутамида или (s)-бикалутамид в качестве активирующих экзоцитоз соединений для применения в лечении расстройства лизосомного накопления или гликогеноза
TWI529396B (zh) 2014-07-18 2016-04-11 Mpi Corp Probe card and its transfer circuit board and signal feed structure
SI4273241T1 (sl) 2014-09-30 2025-03-31 Amicus Therapeutics, Inc. Zelo močna kislinska alfa-glukozidaza z okrepljenimi ogljikovimi hidrati
WO2017049161A1 (en) 2015-09-18 2017-03-23 Duke University ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
NZ786723A (en) 2016-03-30 2025-07-25 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase

Also Published As

Publication number Publication date
KR20250007693A (ko) 2025-01-14
US20210268074A1 (en) 2021-09-02
NZ743230A (en) 2025-06-27
BR112018013151A2 (pt) 2018-12-18
CL2018001773A1 (es) 2018-08-24
CO2018007680A2 (es) 2018-08-10
US11278601B2 (en) 2022-03-22
JP2022058423A (ja) 2022-04-12
US12414985B2 (en) 2025-09-16
US20170189497A1 (en) 2017-07-06
JP2024009829A (ja) 2024-01-23
EA201891507A1 (ru) 2018-12-28
US20250381254A1 (en) 2025-12-18
JP2019501178A (ja) 2019-01-17
JP2025163019A (ja) 2025-10-28
SG11201804965SA (en) 2018-07-30
KR102510941B1 (ko) 2023-03-20
AU2016381832B2 (en) 2024-01-25
IL299470A (en) 2023-02-01
JP7358446B2 (ja) 2023-10-10
WO2017117407A1 (en) 2017-07-06
IL283837B2 (en) 2023-06-01
US10857212B2 (en) 2020-12-08
US20180228877A1 (en) 2018-08-16
KR20230041833A (ko) 2023-03-24
AU2024200071A1 (en) 2024-02-01
MY198085A (en) 2023-07-31
PH12018501313A1 (en) 2019-02-27
US20220370571A1 (en) 2022-11-24
JP7707251B2 (ja) 2025-07-14
MX2022010311A (es) 2022-09-19
CA3010205A1 (en) 2017-07-06
IL283837A (en) 2021-07-29
MX394968B (es) 2025-03-24
KR20180099753A (ko) 2018-09-05
IL259876B (en) 2021-06-30
AU2016381832A1 (en) 2018-06-28
PH12018501313B1 (en) 2024-01-26
KR102747683B1 (ko) 2024-12-31
NZ784003A (en) 2025-06-27
IL259876A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
MX2018008185A (es) Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
MX389350B (es) Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
BR112017002741A2 (pt) peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2018007227A (es) Tratamiento de colestasis intrahepatica y enfermedades hepaticas relacionadas.
MX2020000467A (es) Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer.
EP4285988A3 (en) Treating fibrosis by inhibiting tl1a
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
CO2019012484A2 (es) Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
AU2016303622A8 (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
MY205171A (en) Methods of treatment of hypertriglyceridemia
PH12016000355B1 (en) Use of xanthophylls for the treatment of cancers
EP4285902A3 (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
BR112018016874A2 (pt) métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EA201491048A1 (ru) Соединения двухцепочечных рнк к casp2 и их применение
UA104019U (ru) Способ лечения хронической сердечной недостаточности